MicroRNA 214 inhibits adipocyte enhancer‑binding protein 1 activity and increases the sensitivity of chemotherapy in colorectal cancer

Li,Shouchao; Li,Chengren; Fang,Zhiming

doi:10.3892/ol.2018.9623

MicroRNA 214 inhibits adipocyte enhancer‑binding protein 1 activity and increases the sensitivity of chemotherapy in colorectal cancer

Authors:
- Shouchao Li
- Chengren Li
- Zhiming Fang
View Affiliations

Affiliations: Department of Anorectal Surgery, Weifang People's Hospital, Weifang, Shandong 261000, P.R. China
Published online on: October 26, 2018 https://doi.org/10.3892/ol.2018.9623
Pages: 55-62
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to analyze adipocyte enhancer‑binding protein 1 (AEBP1) expression in colorectal cancer (CRC), with a focus on its possible molecular mechanisms, in order to provide novel insight into the clinical treatment of CRC. Immunohistochemistry (IHC) was used to detect AEBP1 expression in 62 CRC tissues. Kaplan‑Meier survival curves were used to analyze AEBP1 expression and the postoperative disease‑free survival (DFS) and overall survival (OS) rates of CRC patients. HT‑29 cells were treated with oxaliplatin to detect cell proliferation and apoptosis following a Cell Counting kit‑8. Through bioinformatics prediction, microRNA 214 (miR214) was identified as an upstream microRNA of AEBP1 that regulates its expression. IHC revealed that the expression of AEBP1 in CRC tissues was significantly higher than that in adjacent healthy tissues, and that it is associated with Tumor‑Node‑Metastasis stage, recurrence and metastasis. The DFS and OS rates of patients with a low AEBP1 expression were significantly higher than those in patients with a high expression (P<0.05). Following depletion of AEBP1 and treatment with oxaliplatin, the HT‑29 cell proliferation was lower than that of the blank control and the negative control groups. However, the cell apoptosis rate was higher than that of the control group at 72 h (P<0.05). Bioinformatics prediction revealed that miR‑214 is negatively associated with AEBP1 expression, and co‑transfection and luciferase report gene tests revealed that AEBP1 is a target gene of miR‑214. Therefore, AEBP1 may become a novel treatment for CRC patients with chemoresistance and may act through the upstream miR‑214 to participate in the progression of a tumor.

View Figures

View References

1	Fukushima K, Tsuchiya K, Kano Y, Horita N, Hibiya S, Hayashi R, Kitagaki K, Negi M, Itoh E, Akashi T, et al: Atonal homolog 1 protein stabilized by tumor necrosis factor α induces high malignant potential in colon cancer cell line. Cancer Sci. 106:1000–1007. 2015. View Article : Google Scholar : PubMed/NCBI
2	International Agency for Research on Cancer: Estimated incidence, mortality and 5-year prevalence. Both sexes [EB/OL]. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx2017
3	National cancer institute: SEER stat fact sheets. Colon and rectum cancer [EB/OL]. http://seer.cancer.gov/statfacts/html/colorect.html2017.
4	Andersen HS, Bertelsen CA, Henriksen R, Campos AH, Kristensen B, Ingeholm P and Gögenur I: The pathological phenotype of colon cancer with microsatellite instability. Dan Med J. 63(pii): A51982016.PubMed/NCBI
5	van de Velde CJ, Aristei C, Boelens PG, Beets-Tan RG, Blomqvist L, Borras JM, van den Broek CB, Brown G, Coebergh JW, Cutsem EV, et al; EURECCA colorectal, . Multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe. Eur J Cancer. 49:2784–2790. 2013. View Article : Google Scholar : PubMed/NCBI
6	Ku G, Tan IB, Yau T, Boku N, Laohavinij S, Cheng AL, Kang YK and de Lima Lopes G Jr: Management of colon cancer: Resource-stratified guidelines from the Asian oncology summit 2012. Lancet Oncol. 13:e470–e481. 2012. View Article : Google Scholar : PubMed/NCBI
7	Guan X, Chen W, Liu Z, Jiang Z, Hu H, Zhao Z, Wang S, Chen Y, Wang G and Wang X: Whether regional lymph nodes evaluation should be equally required for both right and left colon cancer. Oncotarget. 7:59945–59956. 2016. View Article : Google Scholar : PubMed/NCBI
8	Huang B, Feng Y, Zhu L, Xu T, Huang L and Cai G: Smaller tumor size is associated with poor survival in stage II colon cancer: An analysis of 7,719 patients in the SEER database. Int J Surg. 33:Pt A. 157–163. 2016. View Article : Google Scholar : PubMed/NCBI
9	Bogachev O, Majdalawieh A, Pan X, Zhang L and Ro HS: Adipocyte enhancer-binding protein 1 (AEBP1) (a novel macrophage proinflammatory mediator) overexpression promotes and ablation attenuates atherosclerosis in ApoE (−/-) and LDLR (−/-) mice. Mol Med. 17:1056–1064. 2011. View Article : Google Scholar : PubMed/NCBI
10	Majdalawieh A and Ro HS: Regulation of IkappaBalpha function and NF-kappaB signaling: AEBP1 is a novel proinflammatory mediator in macrophages. Mediators Inflamm. 2010:8238212010. View Article : Google Scholar : PubMed/NCBI
11	Hu W, Jin L, Jiang CC, Long GV, Scolyer RA, Wu Q, Zhang XD, Mei Y and Wu M: AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. Cell Death Dis. 4:e9142013. View Article : Google Scholar : PubMed/NCBI
12	Ladha J, Sinha S, Bhat V, Donakonda S and Rao SM: Identification of genomic targets of transcription factor AEBP1 and its role in survival of glioma cells. Mol Cancer Res. 10:1039–1051. 2012. View Article : Google Scholar : PubMed/NCBI
13	Hu H, Krasinskas A and Willis J: Perspectives on current tumor-node-metastasis (TNM) staging of cancers of the colon and rectum. Semin Oncol. 38:500–510. 2011. View Article : Google Scholar : PubMed/NCBI
14	Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:248–254. 1976. View Article : Google Scholar : PubMed/NCBI
15	Li B, Chen P, Chang Y, Qi J, Fu H and Guo H: Let-7a inhibits tumor cell growth and metastasis by directly targeting RTKN in human colon cancer. Biochem Biophys Res Commun. 478:739–745. 2016. View Article : Google Scholar : PubMed/NCBI
16	Majdalawieh A and Ro HS: PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1. Nucl Recept Signal. 8:e0042010. View Article : Google Scholar : PubMed/NCBI
17	Holloway RW, Bogachev O, Bharadwaj AG, McCluskey GD, Majdalawieh AF, Zhang L and Ro HS: Stromal adipocyte enhancer-binding protein (AEBP1) promotes mammary epithelial cell hyperplasia via proinflammatory and hedgehog signaling. J Biol Chem. 287:39171–39181. 2012. View Article : Google Scholar : PubMed/NCBI
18	Yamashita S, Takahashi S, McDonell N, Watanabe N, Niwa T, Hosoya K, Tsujino Y, Shirai T and Ushijima T: Methylation silencing of transforming growth factor-beta receptor type II in rat prostate cancers. Cancer Res. 68:2112–2121. 2008. View Article : Google Scholar : PubMed/NCBI
19	Sumpio C, Knobf MT and Jeon S: Treatment complexity: A description of chemotherapy and supportive care treatment visits in patients with advanced-stage cancer diagnoses. Support Care Cancer. 24:285–293. 2016. View Article : Google Scholar : PubMed/NCBI
20	Young JI, Mongoue-Tchokote S, Wieghard N, Mori M, Vaccaro GM, Sheppard BC and Tsikitis VL: Treatment and survival of small-bowel adenocarcinoma in the United States: A comparison with colon cancer. Dis Colon Rectum. 59:306–315. 2016. View Article : Google Scholar : PubMed/NCBI
21	Muthalagu N, Junttila MR, Wiese KE, Wolf E, Morton J, Bauer B, Evan GI, Eilers M and Murphy DJ: BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues. Cell Rep. 8:1347–1353. 2014. View Article : Google Scholar : PubMed/NCBI
22	Fang Y, Shen H, Li H, Cao Y, Qin R, Long L, Zhu X, Xie C and Xu W: miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells. Acta Biochim Biophys Sin (Shanghai). 45:963–972. 2013. View Article : Google Scholar : PubMed/NCBI
23	Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M, Sumani KM, Alder H, Amadori D, Patel T, et al: MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci USA. 107:21098–21103. 2010. View Article : Google Scholar : PubMed/NCBI
24	Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GS, Banerjee D and Bertino JR: A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci USA. 104:13513–13518. 2007. View Article : Google Scholar : PubMed/NCBI
25	Qiang R, Wang F, Shi LY, Liu M, Chen S, Wan HY, Li YX, Li X, Gao SY, Sun BC and Tang H: Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa cells. Int J Biochem Cell Biol. 43:632–641. 2011. View Article : Google Scholar : PubMed/NCBI
26	Yang Z, Chen S, Luan X, Li Y, Liu M, Li X, Liu T and Tang H: MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. IUBMB Life. 61:1075–1082. 2009. View Article : Google Scholar : PubMed/NCBI